Hospital Virgen Del Camino — Clinical Trial Site

21 Registered trials

7 Currently recruiting

Organisation

Hospital Virgen Del Camino

Location

Sanlucar De Barrameda, Spain

Identifier

ORG-100044230

Address

Carretera De Chipiona Sn, 11540, Spain

Departments

#2906; Endocrinología
#3438: Med. Interna
Internal Medicine
Medicina Interna
N/A
Servicio Medicina Interna
Virgen del Camino_Medicina Interna1

Clinical trials at this site (21)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
EFFICACY AND SAFETY OF MET097 ONCE WEEKLY IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (VESPER-5) Recruiting

2025-523975-48-00 Obesity 5 2026-05-08
Efficacy And Safety of MET097 Once Weekly In People With Overweight or Obesity (VESPER-4) Recruiting

2025-523974-18-00 Obesity 5 2026-04-30
HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting

2025-523717-29-00 HFpEF or HFmrEF and obesity 5 2026-04-28
A Trial to Test How AZD0780 Affects Serious Heart, Stroke, or Vascular Problems in Patients with Heart, Stroke or Vascular Disease or at Hig… Recruiting

2025-520519-14-00 Atherosclerotic Cardiovascular Disease 5 2025-09-03
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure and a weak pumping functio… Recruiting

2024-519525-38-00 Heart failure 5 2025-08-22
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Recruiting

2023-509706-30-00 Heart failure (HF) 5 2024-10-18
202301CPC Redefine-HF Recruiting

2023-508581-15-00 Heart condition 5 2024-10-08
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended

2025-521067-13-00 Atherosclerotic Cardiovascular Disease (ASCVD) 5 2026-04-24
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MA… Ended

2024-515524-36-00 Chronic Weight Management 5 2025-05-30
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
ATHENA: A research study looking into how ziltivekimab works compared to placebo in people with heart failure and inflammation Ended

2023-506988-34-00 Heart failure with mildly reduced or preserved ejection 5 2024-03-27
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1) Ended

2022-502839-19-00 Obesity 5 2023-09-14
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
REDEFINE 3: A research study to see the effects of CagriSema in people living with diseases in the heart and blood vessels Ended

2023-506924-94-00 Cardiovascular disease 5 2023-02-28
A Study of Tirzepatide (LY3298176) on the Reduction of Morbidity and Mortality in Adults With Obesity (SURMOUNT- MMO) Ended

2022-501744-15-00 Obesity, Overweight 5 2023-01-23
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease … Ended

2023-506926-35-00 Atherosclerotic cardiovascular disease, chronic kidney 5 2021-09-24
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) Ended

2023-503659-88-00 Obesity 5 2023-09-05
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis… Ended

2023-503794-38-00 Prevention of stroke or systemic embolism in atrial fib 5 2022-11-24
Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol,is safe and can have an impact on patient quality of … Ended

2024-511263-28-00 Hypercholesterolemia 6 2022-04-08
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV… Ended

2023-507846-96-00 Type 2 Diabetes Mellitus 5 2020-06-19